Aclarion Inc
ACON
查看详细走势图
5.880USD
-0.110-1.84%
收盘 12/24, 13:00（美东）报价延迟15分钟
3.42M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.84%
5天
-0.34%
1月
-4.62%
6月
-13.53%
今年开始到现在
-99.55%
1年
-99.49%
查看详细走势图
TradingKey Aclarion Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Aclarion Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名210/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价23.00。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Aclarion Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
23.000
目标均价
+291.16%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Aclarion Inc亮点
亮点风险
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Aclarion Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Aclarion Inc简介
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
公司代码ACON
公司Aclarion Inc
CEONess (Brent)
网址https://aclarion.com/
常见问题
Aclarion Inc(ACON)的当前股价是多少？
Aclarion Inc(ACON)的当前股价是 5.880。
Aclarion Inc的股票代码是什么？
Aclarion Inc的股票代码是ACON。
Aclarion Inc股票的52周最高点是多少？
Aclarion Inc股票的52周最高点是3499.510。
Aclarion Inc股票的52周最低点是多少？
Aclarion Inc股票的52周最低点是5.550。
Aclarion Inc的市值是多少？
Aclarion Inc的市值是3.42M。
Aclarion Inc的净利润是多少？
Aclarion Inc的净利润为-7.05M。
现在Aclarion Inc(ACON)的股票是买入、持有还是卖出？
根据分析师评级，Aclarion Inc(ACON)的总体评级为买入，目标价格为23.000。
Aclarion Inc(ACON)股票的每股收益（EPS TTM）是多少
Aclarion Inc(ACON)股票的每股收益（EPS TTM）是-1598.314。
相关品种
